2013 49th ASCO Annual Meeting - účast ČR

Breast Cancer - HER2/ER

Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2

Autoři: Denise Aysel Yardley; Gabriel N. Hortobagyi, MD, FACP; Fabienne Lebrun; J. Thaddeus Beck; Patrick Neven; MD José Baselga, PhD; MUDr. Katarína Petráková, Ph.D.; MD Shaker R. Dakhil, FACP; Sylvia Sabatini; Dr. Anna Komorowski, MD; Dr. Edmond Emilien Chouinard; Robyn R. Young, MD; Prof. Dr. Michael Gnant; Prof. Kathleen I. Pritchard, MD, FRCP; Jie Zhang, PhD; Ryan (Michael) Ziemiecki, MS; Ashok Panneerselvam; Tanya Taran; Tarek Sahmoud; Prof. Shinzaburo Noguchi
Číslo abstraktu: 553
Kategorie: Zhoubné nádory prsu

Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2

Autoři: Mario Campone; Fabienne Lebrun; Prof. Shinzaburo Noguchi; Prof. Kathleen I. Pritchard, MD, FRCP; Howard A. Burris; J. Thaddeus Beck; Yoshinori Ito; Denise Aysel Yardley; Thomas Denis Bachelot; Barbara Pistilli; prof. MUDr. Bohuslav Melichar, Ph.D.; MUDr. Katarína Petráková, Ph.D.; MD Francis P. Arena, FACP; Frans Erdkamp; Wael A. Harb; Jennifer Keating Litton; Ashok Panneerselvam; Mona El-Hashimy; Tanya Taran; Prof. Dr. Michael Gnant
Číslo abstraktu: 557
Kategorie: Zhoubné nádory prsu

Phase (Ph) I/II study of investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): Updated ph II results in patients (pts) with small cell lung cancer (SCLC), non-SCLC (NSCLC), breast cancer (BrC), head and neck squamous cell carcinoma (HN

Autoři: prof. MUDr. Bohuslav Melichar, Ph.D.; Pr. Antoine Adenis; MUDr. Libor Havel; Albert Craig Lockhart, MD; Dr. Jaafar Bennouna; Claudia Schusterbauer; Claudio Dansky Ullmann, MD; Bin Zhang, DSc; Ely Benaim, MD; Prof. M.D. Elizabeth Claire Dees
Číslo abstraktu: 605
Kategorie: Zhoubné nádory prsu

Lack of efficacy of adjuvant lapatinib in HER2-negative breast cancer (HER2–ve BC): Analysis of patients in the TEACH trial

Autoři: Yanin Chavarri Guerra; Prof. M.D. Arlene Chan; Dianne M. Finkelstein; Valorie F. Chan; Vernon J. Harvey; Keun Seok Lee; Minish Mahendra Jain; MUDr. Katarína Petráková, Ph.D.; Vinod Raina; Binghe Xu; Henry Gomez; Erica Rappold; Tomomi Kaneko; Yingjie Huang; Paul E. Goss
Číslo abstraktu: 628
Kategorie: Zhoubné nádory prsu

Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy

Copy number changes in triple-negative breast cancer: New molecular targets.

Autoři: MUDr. Vladimíra Koudeláková (Palková); Mgr. Lenka Radová, Ph.D.; prof. MUDr. Marek Svoboda, Ph.D.; Wenbin Wei; MUDr. Gvantsa Kharaishvili, Ph.D.; doc. Mgr. Jan Bouchal, Ph.D.; RNDr. Radek Trojanec, Ph.D.; doc. MUDr. Marián Hajdúch, Ph.D.; prof. MUDr. Zdeněk Kolář, CSc.; MUDr. Kateřina Bouchalová (Špačková), Ph.D.
Číslo abstraktu: 1063
Kategorie: Zhoubné nádory prsu

Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics

Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with axitinib in patients with previously treated metastatic renal cell cancer (RCC).

Autoři: Ashwin Gollerkeri; Michael S. Gordon; John M. Burke; Ralph J. Hauke, M.D., F.A.C.P; MUDr. Jiří Tomášek, Ph.D.; Donald A. Richards; Christopher DiSimone; Scott S. Tykodi; Amit R. Mehta; Charles Chen; Rachelle Perea; Nicholas J. Vogelzang
Číslo abstraktu: 2533
Kategorie: Genitourinární nádory

Developmental Therapeutics - Immunotherapy

High hydrostatic pressure to induce immunogenic cell death in human tumor cells.

Autoři: Mgr. Iva Truxová; PharmDr Jitka Fučíková, Ph.D.; Mgr. Irena Moserová; Mgr. Simona Partlová; Prof. MUDr. Jiřina Bartůňková, DrSc.; Prof. MUDr. Radek Špíšek, Ph.D.
Číslo abstraktu: 3076
Kategorie: Nádorová biologie/imunologie/genetika a buněčná terapie

Gastrointestinal (Colorectal) Cancer

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC)

Autoři: Kelly S. Oliner; Prof. Jean-Yves Douillard, MD, PhD; Salvatore Siena; Josep Tabernero, MD; Prof. Ronald L. Burkes, MD, FRCP; Mario Edmundo Barugel; Yves Humblet; M.D. György Bodoky, Ph.D.; Prof. David Cunningham, MD, FRCP; prof. dr hab. n. med. Jacek Jassem; Fernando Rivera; doc. MUDr. Ilona Kocáková, Ph.D.; Prof. M.D. Paul Ruff; Maria Blasinska-Morawiec; MUDr. Martin Šmakal; Richard Thomas Williams; Alan Rong; Jeffrey S. Wiezorek; Roger Sidhu; Scott D. Patterson, PhD
Číslo abstraktu: 3511
Kategorie: Gastrointestinální nádory

BRAF and KRAS mutations as additional risk factors in the context of clinical parameters of patients with colorectal cancer.

Autoři: Ing. Vlad Calin Popovici; Mgr. Eva Budinská, Ph.D.; MD Arnaud Roth, CC; Prof. Fred Bosman; Sabine Tejpar, MD; Mauro Delorenzi
Číslo abstraktu: 3522
Kategorie: Gastrointestinální nádory

Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and ziv-aflibercept or placebo in mCRC patients who progressed on prior oxaliplatin treatment.

Autoři: Prof. M.D. Paul Ruff; doc. MUDr. Radek Lakomý, Ph.D.; Doc. MUDr. Jana Prausová, Ph.D., MBA; Dr. Guy van Hazel; Vladimir Mikhailovich Moiseyenko; Prof. Joseph McKendrick; Emmanuelle Boelle, PhD; Remi Castan; Teresa Macarulla, MD; Eric Van Cutsem
Číslo abstraktu: 3574
Kategorie: Gastrointestinální nádory

Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).

Autoři: Tamas Pinter; Esteban Abella; Alvydas Cesas; Adina Croitoru; Jochen Decaestecker; Peter Gibbs; Yevhen Hotko; prof. dr hab. n. med. Jacek Jassem; Galina Petrova Kurteva; MUDr. Jan Novotný, Ph.D.; Seamus O'Reilly; MUDr. Tomáš Šálek, Ph.D.; May F. Mo; L. Mi Rim Choi; Dr. Charles Davic Blanke
Číslo abstraktu: 3575
Kategorie: Gastrointestinální nádory

Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC).

Autoři: Prof. Jean-Yves Douillard, MD, PhD; Salvatore Siena; Josep Tabernero, MD; Prof. Ronald L. Burkes, MD, FRCP; Mario Edmundo Barugel; Yves Humblet; M.D. György Bodoky, Ph.D.; Prof. David Cunningham, MD, FRCP; prof. dr hab. n. med. Jacek Jassem; Fernando Rivera; doc. MUDr. Ilona Kocáková, Ph.D.; Prof. M.D. Paul Ruff; MUDr. Martin Šmakal; Jean-Luc Canon; Mark Rother; Kelly S. Oliner; Ying Tian; Roger Sidhu
Číslo abstraktu: 3620
Kategorie: Gastrointestinální nádory

Connecting gene expression subtypes of colorectal cancer (CRC) with cell lines and drug resistance.

Autoři: Mgr. Eva Budinská, Ph.D.; Jenny Wilding; Ing. Vlad Calin Popovici; Dr. Edoardo Missiaglia; MD Arnaud Roth, CC; Prof. Fred Bosman; Mauro Delorenzi; Walter Bodmer; Sabine Tejpar, MD
Číslo abstraktu: e14544
Kategorie: Gastrointestinální nádory; Kolorektální karcinom

Comparison of efficacy and toxicity of bevacizumab in combination with chemotherapy in the first, second, and third or higher line of treatment for metastatic colorectal carcinoma (mCRC): Data from the Czech multi-institutional registry.

Autoři: doc. MUDr. Igor Kiss, Ph.D., MBA; Mgr. Zbyněk Bortlíček; prof. MUDr. Bohuslav Melichar, Ph.D.; Doc. MUDr. Alexandr Poprach, Ph.D.; MUDr. Jana Halámková, Ph.D.; prof. MUDr. Rostislav Vyzula, CSc.; Prof. RNDr. Ladislav Dušek, Ph.D.; prof. MUDr. Tomáš Büchler, Ph.D.
Číslo abstraktu: e14622
Kategorie: Gastrointestinální nádory; Kolorektální karcinom

Gastrointestinal (Noncolorectal) Cancer

Open-label, phase IIIb, multicenter, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET).

Autoři: Oliver Edgar Bechter; Nicole Unger; Ivan Borbath; Sergio Ricci; Tsann-Long Hwang; Young Suk Park; MUDr. Jiří Tomášek, Ph.D.; Hussein Raef; Sudsawat Laohavinij; Lisa Jean-Louis; Ashok Panneerselvam; Dr. Stephen Saletan; Sotirios G. Stergiopoulos; Prof. Dr. Marianne E. Pavel, M.D.
Číslo abstraktu: 4138
Kategorie: Gastrointestinální nádory

Genitourinary (Nonprostate) Cancer

Randomized phase II study of first-line everolimus plus bevacizumab (E+B) versus interferon α-2a plus bevacizumab (I+B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results.

Autoři: Prof. MD Alain Ravaud, PhD; Prof. MD Carlos Henrique Barrios; MD Boris Alekseev; Miah Hiang Tay; Dr. Sanjiv S. Agarwala; Prof.Dr. Suayib Yalcin; Chia-Chi Lin; Michail Shkolnik; Vsevolod Matveev; Ozlem Anak; Sven Gogov; Diana Pelov; Anne-Laure Louveau; Alexandra Vaury; prof. MUDr. Bohuslav Melichar, Ph.D.
Číslo abstraktu: 4576
Kategorie: Genitourinární nádory

Three lines of targeted therapy for metastatic renal cell carcinoma (mRCC): A viable strategy?

Autoři: prof. MUDr. Tomáš Büchler, Ph.D.; Mgr. Zbyněk Bortlíček; Doc. MUDr. Alexandr Poprach, Ph.D.; MUDr. Kateřina Kubáčková; doc. MUDr. Igor Kiss, Ph.D., MBA; Doc. MUDr. Milada Zemanová, Ph.D.; MUDr. Ondřej Fiala; prof. MUDr. Jitka Abrahámová, DrSc.; prof. MUDr. Bohuslav Melichar, Ph.D.
Číslo abstraktu: e15581
Kategorie: Genitourinární nádory

Genitourinary (Prostate) Cancer

Phase I/II clinical trials of dendritic cell-based immunotherapy in patients with the biochemical relapse of the prostate cancer.

Autoři: Prof. MUDr. Radek Špíšek, Ph.D.; MUDr. Michal Podrazil; prof. MUDr. Marek Babjuk, CSc.; doc. MUDr. Ladislav Jarolím, CSc.; PharmDr Jitka Fučíková, Ph.D.; Anna Fialová; MUDr. Ivo Minárik, FEBU; Mgr. Hana Hromádková; Prof. MUDr. Jiřina Bartůňková, DrSc.
Číslo abstraktu: e16002
Kategorie: Genitourinární nádory

International comparison of androgen-deprivation therapy (ADT) for the treatment of nonmetastatic (M0) prostate cancer (PC)

Autoři: Kirsty Hope; Alex Graham; Jorge Arellano; Alexander Liede
Číslo abstraktu: e16040
Kategorie: Genitourinární nádory

Gynecologic Cancer

Opsalin: A phase II placebo (Pbo)-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with carboplatin (Cb) and paclitaxel (P).

Autoři: Michael J. Birrer; Igor Bondarenko; Sergei Tjulandin; M.D. Ignace Vergote, Ph.D.; prof. MUDr. David Cibula, CSc.; M.D. Isabelle Ray-Coquard; Prof. Dr. Nicoletta Colombo, PhD; Aurore Allard; Corina Oprea; Augustin A. Rey; Cristiana Sessa; M.D. Eric Pujade-Lauraine, Ph.D.
Číslo abstraktu: 5516
Kategorie: Zhoubné gynekologické nádory

Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

Autoři: Charles Andrew Butts; Mark A. Socinski; Paul Mitchell; Nick Thatcher; MUDr. Libor Havel; Maciej Jerzy Krzakowski; Sergiusz Nawrocki; Tudor Ciuleanu; Lionel Bosquée; Jose Manuel Trigo Perez; Alexander I. Spira; Lise Tremblay; Jan Nyman; Rodryg Ramlau; Christoph Helwig; Martin H. Falk; Frances A. Shepherd
Číslo abstraktu: 7500
Kategorie: Zhoubné nádory plic a průdušek

Thymic carcinoma: A cohort study of prognostic factors after surgical resection from the European Society of Thoracic Surgeons database.

Autoři: Enrico Ruffini; Frank C. Detterbeck, MD, FACS, FCCP; Dirk Van Raemdonck, MD, PhD, FETCS; Dr. Gaetano Rocco, FRCSEd; Pascal Alexandre Thomas; Prof. Dr. Walter Weder, FRCS; MD Alessandro Brunelli; Francesco Guerrera; Shaf Keshavjee; MD Nasser K. Altorki; Prof. MUDr. Jan Schützner, CSc.; Prof. Dr. Alper Toker; Lorenzo Spaggiari; MD Alex Arame, PhD; Eric Kian Saik Lim, MB, ChB, MSc, MD, FRCS(C-Th); Prof. Federico Venuta
Číslo abstraktu: 7602
Kategorie: Zhoubné nádory plic a průdušek

Lung Cancer - Non-small Cell Metastatic

Prospective randomised phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) with nonsquamous (Non SCC) histological type. NAVoTRI

Autoři: Dr. Jaafar Bennouna; MUDr. Libor Havel; Maciej Jerzy Krzakowski; Jens Kollmeier; MD Radj Gervais; Eric Dansin; Monika Serke; Adolfo G. Favaretto; Manuel Cobo; Aleksandra Szczesna; Libero Ciuffreda; prof. dr hab. n. med. Jacek Jassem; Mario Nicolini; Rodryg Ramlau; Dr. Domenico Amoroso; Barbara Melotti; MD Teresa Almodovar; Nathalie Vaissiere; Marcello Riggi; Eng Huat Tan
Číslo abstraktu: 8043
Kategorie: Zhoubné nádory plic a průdušek

Lymphoma and Plasma Cell Disorders

Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD)

Autoři: MD Antonio P. Palumbo; MD Sara Bringhen; Prof. Dr. S. Vincent Rajkumar; Giulia Lupparelli, PhD; Dr. Saad Zafar Usmani; Prof. Anders Waage; MD Alessandra Larocca; Bronno van der Holt; MD Pellegrino Musto; Andrea Evangelista, PhD; MD Sonja Zweegman, PhD; Meletios Athanasios Dimopoulos, MD; prof. MUDr. Roman Hájek, CSc.; MD Michele Cavo; Prof. MD Sagar Lonial; MD Giovannino Ciccone, PhD; MD Mario Boccadoro; Prof. MD Bart Barlogie, PhD; MD Pieter Sonneveld, PhD.; Philip L. McCarthy, BA, MD
Číslo abstraktu: 8517
Kategorie: Maligní lymfomy a leukémie

Lenalidomide (LEN)-melphalan-prednisone induction followed by LEN maintenance (MPR-R) in newly diagnosed multiple myeloma (NDMM) elderly patients (Pts) with moderate renal impairment (RI): MM-015 trial post-hoc analysis.

Autoři: MBBS John V. Catalano, FRACP FRCPA; MD Antonio P. Palumbo; MD Katja C. Weisel; Meletios Athanasios Dimopoulos, MD; MD Michel Delforge, PhD; Prof. Dr. Joan Bladé, PhD; MD Maria Teresa Petrucci; MD Martin (H.) Kropff; prof. MUDr. Roman Hájek, CSc.; Christian J. Jacques; Zhinuan Yu, PhD; Lindsey Herbein; MD Michele Cavo
Číslo abstraktu: 8544
Kategorie: Maligní lymfomy a leukémie

Patient and Survivor Care

Something to sing about: A global choir of cancer survivors—Building bridges

Autoři: Dr. Paul P. Donnellan; Donal Gill; Deanna Hynes; Olive Gallagher; Seamus Leonard
Číslo abstraktu: e20505
Kategorie: Organizace, hodnocení a standardizace onkologické péče

Tumor Biology

Prognostic significance of ATP-binding cassette (ABC) and solute carrier (SLC) transporters in pancreatic ductal adenocarcinoma (PDAC).

Autoři: MUDr. Beatrice Mohelníková-Duchoňová; Mgr. Veronika Brynychová; Doc. MUDr. Martin Oliverius, Ph.D., FEBS; MUDr. Jan Hlavsa; MUDr. Eva Honsová, Ph.D.; MUDr. Jan Mazanec; prof. MUDr. Bohuslav Melichar, Ph.D.; prof. MUDr. Zdeněk Kala, CSc.; RNDr. Pavel Souček, CSc.
Číslo abstraktu: 11051
Kategorie: Nádorová biologie/imunologie/genetika a buněčná terapie

Clinical importance of circulating tumor cells in lung cancer patients.

Autoři: Mgr. Andrea Benedíková; MUDr. Josef Srovnal, Ph.D.; prof., MUDr. Jiří Klein, Ph.D., PETCS; MUDr.Mgr. Pavel Skalický, Ph.D.; MUDr. Marek Szkorupa; MUDr. Karel Cwiertka, Ph.D.; Mgr. Lenka Radová, Ph.D.; doc. MUDr. Marián Hajdúch, Ph.D.
Číslo abstraktu: e22109
Kategorie: Nádorová biologie/imunologie/genetika a buněčná terapie

Dynamics of T-cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T cells.

Autoři: Mgr. Simona Partlová; Anna Fialová; Luděk Sojka; prof. MUDr. Lukáš Rob, CSc.; Prof. MUDr. Jiřina Bartůňková, DrSc.; Prof. MUDr. Radek Špíšek, Ph.D.
Číslo abstraktu: e22129
Kategorie: Nádorová biologie/imunologie/genetika a buněčná terapie

Association of cyclin D2 downregulation with adverse prognostic factors and survival: Analysis of D-type cyclins, cyclin E1, p27, and ki-67 mRNA in breast carcinomas.

Autoři: Mgr. Helena Břízová; RNDr. Marcela Mrhalová, Ph.D.; prof. MUDr. Roman Kodet, CSc.
Číslo abstraktu: e22208
Kategorie: Nádorová biologie/imunologie/genetika a buněčná terapie